Review highlights novel drug therapy targets and mechanisms for myocardial ischemia-reperfusion injury, suggesting new preventive strategies.
Myocardial ischemia-reperfusion injury is a significant complication of reperfusion therapy and a primary cause of mortality in patients with acute myocardial infarction. The pathogenic mechanism involved in myocardial ischemia-reperfusion injury is intricate, and effective preventive and therapeutic strategies remain limited in clinical practice. Recently, pyroptosis has emerged as a novel regulatory form of cell death and has attracted widespread attention as a key focus in the study of disease mechanisms and therapeutic targets. Studies indicate a close association between pyroptosis and the pathophysiological processes underlying myocardial ischemia-reperfusion injury. This article provides a comprehensive review of recent advances in research on pyroptosis in the context of myocardial ischemia-reperfusion injury. Therefore, this review aims to offer new insights into the prevention and treatment of myocardial ischemia-reperfusion injury while minimizing redundancy in the existing literature.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: